Altimmune Hit By Nasal COVID-19 Vaccine Failure, But Has A Plan B
Obesity Candidate Shows Promise
Executive Summary
Altimmune’s hopes of bringing a nasal COVID-19 vaccine to market have been dashed, but it is pivoting to novel peptide-based therapies.